<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523159</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT Nr: 2006-006370-25</org_study_id>
    <nct_id>NCT00523159</nct_id>
  </id_info>
  <brief_title>IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease</brief_title>
  <acronym>IMA901-202</acronym>
  <official_title>Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>immatics Biotechnologies GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>immatics Biotechnologies GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine
      IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.

      Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9
      months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior
      to the first vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, randomized phase 2 study which investigated the effect of
      a second-line systemic treatment with IMA901 plus GM-CSF in RCC patients. Randomization was
      done according to a pre-treatment with low-dose cyclophosphamide (CY). Secondary endpoints
      comprised tumor response parameters.

      The study population consisted of HLA-A*02-positive men or women with advanced RCC of the
      clear-cell type classified as having a favorable or intermediate risk after first-line
      systemic therapy for. Patients had to be aged 18 years or older, had at least have one
      measurable tumor lesion and had have received first-line tyrosine kinase inhibitor or
      cytokine systemic therapy for advanced disease, during or after which the patient had
      experienced disease progression.

      Patients in both arms received a total of 17 vaccinations with GM-CSF followed by IMA901
      during the 9 month treatment period.

      At screening baseline tumor status was assessed by CT or MRI. During the study tumor
      assessments were performed every 6 weeks.

      Immunomonitoring (T-cell responses to peptides contained in IMA901 and analysis of other
      immune cell populations that may influence T-cell responses), serum levels of antibodies and
      molecules with suspected influence on immune response were assessed on several occasions
      during the study.

      Safety assessment comprised continuous adverse event reporting, regular physical examinations
      and regular assessments of vital signs, hematology, blood chemistry and urine. A 12-lead ECG
      was performed at screening and at the end of the study. Pregnancy testing was performed
      according to applicable legislation in the country where the trial was performed. At the very
      least, women of childbearing potential had have to undergo a pregnancy test during screening
      for the study, before the first dose was applied and at the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>after 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rates and SD rate</measure>
    <time_frame>after 26 and 38 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from the time response is first documented until the first date of recurrence or PD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>From Visit c to PR or CR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>From visit C to until tumor progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS and OS</measure>
    <time_frame>From visit C to tumor progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>after 38 weeks on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>Visit C, 1, 5, 6, 7, 10 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of cyclophosphamide pre-treatment on immune response</measure>
    <time_frame>Visit C, 1, 5,6,7, 10, 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>From inclusion on the study until 3 weeks after end of study visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endoxana, IMA901, Leukine</intervention_name>
    <description>a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMA901 and Leukine</intervention_name>
    <description>Intradermal injection of GM-CSF followed by intradermal injection of IMA901</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 18 years

          -  HLA type: HLA-A*02-positive

          -  Histologically documented advanced clear-cell RCC

          -  Patients who have received first-line tyrosine kinase inhibitor or cytokine systemic
             therapy for advanced disease systematic therapy for advanced disease and must be
             candidates for second-line therapy (NOTE: in Germany and Austria only patients after
             first-line tyrosine kinase inhibitor failure will be included into the study)

          -  Patients having experienced documented tumor progression

          -  At least one unidimensional measurable target lesion

          -  Karnofsky Performance Status ≥ 80%

          -  Favorable or intermediate risk according to the 3-score MSKCC criteria.

          -  Able to understand the nature of the study and give written informed consent

          -  Willingness and ability to comply with the study protocol for the duration of the
             study

        Exclusion Criteria:

          -  Poor risk according to the 3-score MSKCC criteria

          -  Immunosuppressive therapy within 4 weeks before study entry, e.g. corticosteroid
             treatment

          -  History of other malignant tumors, except non-melanoma-skin cancer or curatively
             excised cervical carcinoma in situ

          -  Presence of brain metastases on MRI or CT scan

          -  Patients with a history or evidence of systemic autoimmune disease

          -  Any vaccination in the two weeks before study entry

          -  Any planned prophylactic vaccination from study entry until the end of the induction
             period (5 weeks after the first vaccination)

          -  Known active hepatitis B or C infection

          -  Known HIV infection

          -  Any other infection with a biological agent that can cause a severe disease and poses
             a severe danger to lab personnel working on patient tissues.

          -  Any of the following in the 4 weeks before study entry:

               1. Major surgery

               2. Anticancer treatments including (but not limited to) cytotoxic chemotherapy,
                  radiotherapy, immunotherapy, hormone therapy, tyrosine kinase inhibitors,
                  monoclonal antibodies

               3. Unresolved toxicity from prior anticancer treatments including (but not limited
                  to) cytotoxic chemotherapy, hormone therapy, tyrosine kinase inhibitors,
                  monoclonal antibodies, radiotherapy, or immunotherapy

               4. Received study drug within any clinical study

          -  Any of the following abnormal laboratory values:

               1. Hematology: Hb &lt; 9 g/dL; WBC &lt; 3 x 109/L; neutrophils &lt; 1.5 x 109/L; lymphocytes
                  &lt; 1.0 x 109/L; platelets &lt; 100 x 109/L

               2. Liver function: serum bilirubin &gt; 1.5 x upper normal limit (unless a history of
                  Gilbert's disease); ALAT or ASAT &gt; 3 x upper normal limit (&gt;5 x upper normal
                  limit if liver metastases are present)

               3. Renal function: serum creatinine &gt; 200 µmol/L

          -  Patients with other significant diseases currently uncontrolled by treatment which
             might interfere with study completion, for example:

               1. Heart failure or non compensated active heart disease

               2. Severe coronary heart disease, cardiac arrhythmia requiring medication, or
                  uncontrolled hypertension

               3. Symptomatic neurotoxicity (motor or sensory) ≥ grade 2 National Cancer Institute
                  - Common Toxicity Criteria (NCI-CTC).

               4. Severe pulmonary dysfunction

          -  Psychiatric disabilities, seizures or central nervous system disorders that may
             interfere with the ability to give informed consent or perform adequate follow-up in
             the investigator's opinion

          -  Active infections requiring oral or intravenous antibiotics

          -  Women or men who decline to practice a medically approved method of contraception

          -  Pregnancy or breastfeeding

          -  Any condition which in the judgment of the investigator would place the patient at
             undue risk or interfere with the results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Kirner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>immatics Biotechnologies GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Salzburg - Universitätsklinik für Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Oncology Hospital - Urology</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncodispensary with inpatient sector-Sofia District</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte-Klinik für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin - Medizinische Klinik III</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeisigwaldkliniken Bethanien Chemnitz GmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Johann-Wolfgang-Goethe-Universität</name>
      <address>
        <city>Frankfurt / Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum (Onkologie / Hämatologie)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg - Klinik für Urologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein - Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz - 3. Medizinische Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität - München Großhadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik Dr. Castringius - München-Planegg</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen - Klinik für Urologie</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar-Klinik - Abt. Hämatologie und Onkologie</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC Gyógyszervizsgáló Központ Kft</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Urológiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Kórház - Urológia Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fövárosi Önk.Szt.Imre Kórház - Belgyógyászat-Kliniko-FFarmakológia</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet - Kemoterápia C osztály-Klinikofarmakológia</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos és Egészségtudományi Centrum</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hajdú-Bihar Megyei Önk. Kenézy Gyula Kórház/Urológia Osztály</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAZ megyei Kórház - Urológia Osztály</name>
      <address>
        <city>Miskolc</city>
        <zip>3501</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécs Orvostudomanyi Egyetem - Urológiai Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chemioterapii Nowotworow - Uniwersytetu Medycznego</name>
      <address>
        <city>Lodz</city>
        <zip>93509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii Wojskowego Institutu Medycznego</name>
      <address>
        <city>Warszawa</city>
        <zip>00909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Urology and Urological Oncology Medica University Hospital</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-043</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute &quot;Prof. Dr. Alexandru Trestioreanu&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute - &quot;Prof. Dr. Alexandru Trestioreanu&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute &quot;Prof. Dr. Ion Chiricuta&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical County Hospital Oradea</name>
      <address>
        <city>Oradea</city>
        <zip>4170167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institut - &quot;Narodny onkologicky ustav&quot;</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Radiotherapy and Oncology - East Slovak Oncology Institute</name>
      <address>
        <city>Kosice</city>
        <zip>04191</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Faculty Hospital</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Oncology - Faculty Hospital with Policlinic of J.A. Reiman</name>
      <address>
        <city>Presov</city>
        <zip>08181</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra - Servicio de Oncologia</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Medicine Oncology</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust, CRUK Department of Medical Onkology - Paterson Institute for Cancer Research</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Surrey - Postgraduate Medical School</name>
      <address>
        <city>Surrey</city>
        <zip>GU2 7WG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>July 9, 2012</last_update_submitted>
  <last_update_submitted_qc>July 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

